SCHEMBL2301334

SCHEMBL2301334

COC(=O)C(NC(=O)c1csc(-c2ccc(NC(=O)Nc3ccc(C)c(C)c3)cc2)n1)C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.52
CSGALNACT1 Q8TDX6 3/20 0.52
TSHR P16473 1/20 0.48
RECQL P46063 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.43
MCL1 Q07820 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MEN1 O00255 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 1/20 0.42
MAPT P10636 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2301344 1.00 DGAT1 (0.52) DGAT1CSGALNACT1TSHRRECQLTAS1R3
SCHEMBL2300059 0.90 DGAT1 (0.64) DGAT1CSGALNACT1TDP1MAPTNPY1R
SCHEMBL2300052 0.90 DGAT1 (0.64) DGAT1CSGALNACT1TDP1MAPTNPY1R
SCHEMBL2301342 0.88 CSGALNACT1 (0.52) CSGALNACT1SMN1; SMN2MEN1CYP2C9CYP2C19
SCHEMBL2301345 0.88 CSGALNACT1 (0.52) CSGALNACT1SMN1; SMN2MEN1CYP2C9CYP2C19
SCHEMBL2300971 0.85 NPC1 (0.47) SMN1; SMN2MEN1KMT2ATDP1NPC1
SCHEMBL2300968 0.85 NPC1 (0.47) SMN1; SMN2MEN1KMT2ATDP1NPC1
SCHEMBL2293740 0.84 MAPK1 (0.58) DGAT1CSGALNACT1SMN1; SMN2MEN1KMT2A
SCHEMBL2293738 0.84 MAPK1 (0.58) DGAT1CSGALNACT1SMN1; SMN2MEN1KMT2A
SCHEMBL1756219 0.83 DGAT1 (0.57) DGAT1CSGALNACT1TSHRRECQLTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT DGAT1 1/4885CSGALNACT1 455/4885TSHR 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.